Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03388788 · ClinicalTrials.gov registry record

Body Weight, Sleep, and Heart Health

A clinical trial of Obesity and Cardiovascular Risk Factor, sponsored by Oregon Health and Science University.

Active
Registry status
16
Enrollment target
1
Study location

NCT03388788: Active study of Obesity and Cardiovascular Risk Factor, sponsored by Oregon Health and Science University.

NCT03388788 is a study of Obesity and Cardiovascular Risk Factor that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 16 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03388788, a study of Obesity and Cardiovascular Risk Factor, is active but no longer recruiting, sponsored by Oregon Health and Science University.

ACTIVE NOT RECRUITING
Registry status
16 participants
Enrollment target
1
Study location

Study Summary

A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk, with an additional focus on obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in these risk markers to standardized stressors. It is intended to compare results in lean and obese individuals to determine if there are specific risks across the circadian cycle specific to obesity. Furthermore, using an exploratory approach, the investigators propose to explore impairment in pre/post synaptic function in the cardiac left ventricle.

Primary Outcome

Measurements were collected up to 7 times per participant across the circadian cycle under constant conditions across 5 days. Resting BP and Exercise BP data were collected at the beginning of each of 7 wake periods in a supine position and where participants exercised at an intensity equivalent to brisk walking. Salivary melatonin was used to calculate the circadian phase marker using dim light melatonin onset (DLMO). All data were assigned a circadian phase relative to DLMO and binned into 4-h

Interventions

  • COMBINATION_PRODUCT Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-05-01
Est. Completion 2026-06-30

What the registry record for NCT03388788 still lists

NCT03388788 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle is the first listed.

NCT03388788 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT03388788 about?

NCT03388788 is a clinical study titled "Body Weight, Sleep, and Heart Health". A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk, with an additional focus on obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in th...

What is the current status of trial NCT03388788?

This trial is currently active not recruiting. The enrollment target is 16 participants. The study started on 2018-05-01. Estimated completion is 2026-06-30.

What conditions does trial NCT03388788 study?

This clinical trial studies the following conditions: Obesity, Cardiovascular Risk Factor, Circadian Dysregulation.

What interventions are being tested in trial NCT03388788?

The interventions under investigation include: Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03388788?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03388788 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03388788's enrollment target sits among peer trials

16 993rd of 1053 higher than 56 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03388788, the US trial registry maintained by the National Library of Medicine. NCT03388788 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.